Input your search keywords and press Enter.

Pfizer’s COVID-19 vaccine trial data shows long-term efficacy


Pfizer said on Monday its COVID-19 vaccine provided strong long-term protection against the virus in a late-stage study conducted among adolescents aged 12 to 15 years.

A two-dose series of the vaccine was 100% effective against COVID-19, measured seven days through over four months after the second dose, the company said.

Related: Pfizer COVID-19 vaccine shows 90.7% efficacy in trial in children 

The long-term data will support planned submissions for full-regulatory approval of the vaccine in the age group in the United States and worldwide.

Pfizer and BioNTech will seek clearance for a 30 micrograms dose of the vaccine for those aged 12 and above.

The vaccine was authorized for emergency use in people aged 12-15 years by the U.S. Food & Drug Administration in May, and granted full approval for use in people aged 16 and above in August.

Facebook Notice for EU!
You need to login to view and post FB Comments!





Source link

Leave a Reply

Your email address will not be published. Required fields are marked *